Acadia Pharmaceuticals Inc. (ACAD)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS0042251084
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Acadia Pharmaceuticals Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:29. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | 0.26 | — | — | Upcoming |
| 04 Nov 2026 16:00 | 0.18 | 0.31 | +69.9% | Beat |
| 04 Aug 2026 16:00 | 0.04 | 0.18 | +317.3% | Beat |
| 06 May 2026 16:00 | 0.08 | 0.02 | -75.2% | Miss |
| 25 Feb 2026 16:00 | 0.14 | 0.14 | -4.2% | Miss |
| 05 Nov 2025 16:00 | 0.15 | 0.42 | +189.0% | Beat |
| 06 Aug 2025 16:00 | 0.14 | 0.16 | +15.3% | Beat |
| 07 May 2025 16:00 | 0.11 | 0.11 | +4.5% | Beat |
| 26 Feb 2025 16:00 | 0.22 | 0.86 | +292.6% | Beat |
| 06 Nov 2024 16:00 | 0.14 | 0.20 | +41.2% | Beat |
| 06 Aug 2024 16:00 | 0.18 | 0.20 | +13.9% | Beat |
| 08 May 2024 16:00 | 0.06 | 0.10 | +67.0% | Beat |
| 27 Feb 2024 16:00 | 0.31 | 0.28 | -9.5% | Miss |
| 02 Nov 2023 16:00 | -0.42 | -0.40 | +5.4% | Beat |
| 02 Aug 2023 16:00 | -0.12 | 0.01 | +108.6% | Beat |
| 08 May 2023 16:00 | -0.21 | -0.27 | -28.7% | Miss |
| 27 Feb 2023 16:00 | -0.25 | -0.26 | -3.8% | Miss |
| 02 Nov 2022 16:00 | -0.20 | -0.17 | +13.0% | Beat |
| 08 Aug 2022 16:00 | -0.25 | -0.21 | +15.0% | Beat |
| 04 May 2022 16:00 | -0.60 | -0.70 | -17.3% | Miss |
| 28 Feb 2022 16:00 | -0.24 | -0.27 | -14.2% | Miss |
| 08 Nov 2021 16:00 | -0.26 | -0.09 | +65.1% | Beat |
| 04 Aug 2021 16:00 | -0.30 | -0.27 | +8.7% | Beat |
| 05 May 2021 16:00 | -0.53 | -0.42 | +20.6% | Beat |
| 24 Feb 2021 16:00 | -0.47 | -0.42 | +11.1% | Beat |
| 04 Nov 2020 16:00 | -0.38 | -0.54 | -42.3% | Miss |
| 05 Aug 2020 16:00 | -0.43 | -0.27 | +37.7% | Beat |
| 07 May 2020 17:00 | -0.47 | -0.57 | -22.6% | Miss |
| 26 Feb 2020 16:00 | -0.36 | -0.34 | +6.7% | Beat |
| 30 Oct 2019 16:00 | -0.40 | -0.29 | +27.3% | Beat |
| 31 Jul 2019 16:00 | -0.46 | -0.38 | +17.2% | Beat |
| 01 May 2019 16:00 | -0.53 | -0.59 | -11.8% | Miss |
| 26 Feb 2019 16:00 | -0.55 | -0.50 | +9.2% | Beat |
| 06 Nov 2018 16:00 | -0.58 | -0.50 | +13.2% | Beat |
| 08 Aug 2018 16:00 | -0.45 | -0.51 | -13.6% | Miss |
| 04 May 2018 07:00 | -0.56 | -0.44 | +21.4% | Beat |
| 27 Feb 2018 16:00 | -0.57 | -0.55 | +3.5% | Beat |
| 07 Nov 2017 16:00 | -0.63 | -0.53 | +15.3% | Beat |
| 08 Aug 2017 16:00 | -0.72 | -0.55 | +24.0% | Beat |
| 09 May 2017 16:00 | -0.72 | -0.72 | 0.0% | In line |
| 28 Feb 2017 16:00 | -0.63 | -0.65 | -2.6% | Miss |
| 07 Nov 2016 16:00 | -0.57 | -0.61 | -6.5% | Miss |
| 04 Aug 2016 16:00 | -0.47 | -0.63 | -33.8% | Miss |
| 05 May 2016 16:00 | -0.42 | -0.45 | -8.2% | Miss |
| 29 Feb 2016 07:00 | -0.41 | -0.45 | -9.3% | Miss |
| 05 Nov 2015 16:00 | -0.39 | -0.39 | +1.2% | Beat |
| 06 Aug 2015 16:00 | -0.33 | -0.39 | -19.3% | Miss |
| 07 May 2015 16:00 | -0.26 | -0.40 | -51.1% | Miss |
| 26 Feb 2015 16:00 | -0.26 | -0.28 | -8.9% | Miss |
| 10 Nov 2014 16:00 | -0.22 | -0.25 | -14.5% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 1.1B | +11.9% | 391M | 36.5% | 2.30 | +69.1% | 105.1M |
| 2024 | 957.8M | +31.8% | 226.5M | 23.6% | 1.36 | +467.6% | 157.2M |
| 2023 | 726.4M | +40.4% | -61.3M | -8.4% | -0.37 | +72.4% | 16.7M |
| 2022 | 517.2M | — | -216M | -41.8% | -1.34 | — | -114M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 20.71 | 22.63 | 15.86 | 18.08 | -12.19% | 38,578,399 | |
| Oct 2026 | 19.95 | 21.01 | 18.39 | 20.59 | +2.18% | 37,690,100 | |
| Sep 2026 | 28.84 | 29.75 | 19.80 | 20.15 | -30.30% | 45,214,700 | |
| Aug 2026 | 25.96 | 30.96 | 25.43 | 28.91 | +11.75% | 36,913,100 | |
| Jul 2026 | 25.24 | 26.58 | 24.23 | 25.87 | +2.25% | 31,299,800 | |
| Jun 2026 | 21.40 | 27.31 | 20.75 | 25.30 | +16.81% | 35,055,500 | |
| May 2026 | 22.31 | 23.07 | 20.30 | 21.66 | -3.52% | 34,880,100 | |
| Apr 2026 | 22.22 | 22.89 | 20.96 | 22.45 | +0.85% | 35,974,900 | |
| Mar 2026 | 24.21 | 24.34 | 19.89 | 22.26 | -9.36% | 43,685,300 | |
| Feb 2026 | 25.29 | 26.23 | 21.51 | 24.56 | -2.27% | 33,258,000 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Acadia Pharmaceuticals Fell While Sales Rose (opens in a new tab) Simply Wall St. · 10 Nov 2026 06:11
- Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal (opens in a new tab) 10 Nov 2026 04:47
- Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Today (opens in a new tab) Simply Wall St. · 10 Nov 2026 04:29
- Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued? (opens in a new tab) Simply Wall St. · 10 Nov 2026 01:17
- Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference (opens in a new tab) 09 Nov 2026 21:05
- Acadia Pharmaceuticals Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 08 Nov 2026 23:13
- Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38 (opens in a new tab) Benzinga · 06 Nov 2026 15:50
- Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says (opens in a new tab) MT Newswires · 05 Nov 2026 17:07
- RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38 (opens in a new tab) Benzinga · 05 Nov 2026 14:19
- ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Debut Sales and ... (opens in a new tab) 05 Nov 2026 07:15
- ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Daybue Sales and ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 07:15
- Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 01:34
- What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 05 Nov 2026 01:14
- Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 04 Nov 2026 23:45
- Acadia: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 04 Nov 2026 21:57
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 18.14 USD
- Market cap
- 3.1B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow ACAD and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.